The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows"

被引：1

作者：

Delcuratolo, Marco Donatello ^{[1
,5
]}

Crespi, Veronica ^{[2
,5
]}

Saba, Giorgio ^{[3
,4
,5
]}

Mogavero, Andrea ^{[5
]}

Napoli, Valerio Maria ^{[5
]}

Garbo, Edoardo ^{[5
]}

Cani, Massimiliano ^{[5
]}

Ungaro, Antonio ^{[6
]}

Reale, Maria Lucia ^{[7
]}

Merlini, Alessandra ^{[5
]}

Capelletto, Enrica ^{[5
]}

Bironzo, Paolo ^{[5
]}

Levis, Mario ^{[8
]}

Ricardi, Umberto ^{[8
]}

Novello, Silvia ^{[5
]}

Passiglia, Francesco ^{[5
]}

机构：

[1] Fdn IRCCS, Med Oncol Unit, Casa Sollievo Sofferenza, San Giovanni Rotondo, FG, Italy

[2] Asst Sette Laghi, Dept Med Oncol, Varese, Italy

[3] Univ Hosp, Med Oncol Unit, I-09042 Cagliari, Italy

[4] Univ Cagliari, I-09042 Cagliari, Italy

[5] Univ Turin, Dept Oncol, AOU S Luigi Gonzaga, Orbassano, TO, Italy

[6] San Giuseppe Moscati Hosp, Med Oncol Unit, Statte, TA, Italy

[7] Vito Fazzi Hosp, Med Oncol Unit, Lecce, Italy

[8] Univ Turin, Dept Oncol, Radiat Oncol Unit, AOU Citta Salute & Sci, Turin, Italy

来源：

CANCER TREATMENT REVIEWS | 2025年 / 135卷

关键词：

stage III; Locally advanced; Unresectable; Immunotherapy; Non-small cell lung cancer; WORLD TREATMENT PATTERNS; CIRCULATING TUMOR DNA; REAL-WORLD; CONCURRENT CHEMORADIOTHERAPY; CLINICAL-OUTCOMES; PHASE-III; PLUS CHEMOTHERAPY; PROGRESSION-FREE; DURVALUMAB; NSCLC;

D O I：

10.1016/j.ctrv.2025.102918

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting; the activity of less intensive regimens for frail populations; the role of targeted therapies in oncogene-addicted tumors; the selection of subsequent strategies at immunotherapy failure; the efficacy of novel and intensified treatments; the role of molecular biomarkers for patients' selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.

引用

页数：11

共 104 条

[61]

Meng X, 2024, 2024 INT ASS STUD LU

[62] Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer [J].

Moding, Everett J. ;

Liu, Yufei ;

Nabet, Barzin Y. ;

Chabon, Jacob J. ;

Chaudhuri, Aadel A. ;

Hui, Angela B. ;

Bonilla, Rene F. ;

Ko, Ryan B. ;

Yoo, Christopher H. ;

Gojenola, Linda ;

Jones, Carol D. ;

He, Jianzhong ;

Qiao, Yawei ;

Xu, Ting ;

Heymach, John V. ;

Tsao, Anne ;

Liao, Zhongxing ;

Gomez, Daniel R. ;

Das, Millie ;

Padda, Sukhmani K. ;

Ramchandran, Kavitha J. ;

Neal, Joel W. ;

Wakelee, Heather A. ;

Loo, Billy W., Jr. ;

Lin, Steven H. ;

Alizadeh, Ash A. ;

Diehn, Maximilian .

NATURE CANCER, 2020, 1 (02) :176-+

[63] Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC [J].

Naidoo, Jarushka ;

Antonia, Scott ;

Wu, Yi-Long ;

Cho, Byoung Chul ;

Thiyagarajah, Piruntha ;

Mann, Helen ;

Newton, Michael ;

Faivre-Finn, Corinne .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) :657-663

[64] Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC [J].

Nassar, Amin H. ;

Jayakrishnan, Ritujith ;

Feng, Jamie ;

Shepherd, Frances ;

Adib, Elio ;

Cheung, Justin M. ;

Lin, Jessica J. ;

Liu, Yufei ;

Lin, Steven H. ;

Parikh, Kaushal ;

Sridhar, Arthi ;

Shakya, Purnima ;

Dilling, Thomas J. ;

Kaldas, David ;

Gray, Jhanelle E. ;

Lobachov, Anastasiya ;

Bar, Jair ;

Luders, Heike ;

Grohe, Christian ;

Gupta, Shruti ;

Leal, Ticiana ;

Fitzgerald, Bailey ;

Crowley, Fionnuala ;

Fujiwara, Yu ;

Marron, Thomas U. ;

Wilgucki, Molly ;

Reuss, Joshua ;

Chen, Luxi ;

Sankar, Kamya ;

Aredo, Jacqueline, V ;

Neal, Joel W. ;

Wakelee, Heather A. ;

Thummalapalli, Rohit ;

Yu, Helena ;

Whitaker, Ryan ;

Velazquez, Ana ;

Ragavan, Meera ;

Cortellini, Alessio ;

Kwiatkowski, David J. ;

Naqash, Abdul Rafeh ;

Goldberg, Sarah B. ;

Kim, So Yeon .

JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) :109-118

[65] Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT) [J].

Ohri, Nitin ;

Jolly, Shruti ;

Cooper, Benjamin T. ;

Kabarriti, Rafi ;

Bodner, William R. ;

Klein, Jonathan ;

Guha, Chandan ;

Viswanathan, Shankar ;

Shum, Elaine ;

Sabari, Joshua K. ;

Cheng, Haiying ;

Gucalp, Rasim A. ;

Castellucci, Enrico ;

Qin, Angel ;

Gadgeel, Shirish M. ;

Halmos, Balazs .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (05)

[66] Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients [J].

Pan, Yi ;

Zhang, Jia-Tao ;

Gao, Xuan ;

Chen, Zhi-Yong ;

Yan, Bingfa ;

Tan, Pei-Xin ;

Yang, Xiao-Rong ;

Gao, Wei ;

Gong, Yuhua ;

Tian, Zihan ;

Liu, Si-Yang Maggie ;

Lin, Hui ;

Sun, Hao ;

Huang, Jie ;

Liu, Si-Yang ;

Yan, Hong-Hong ;

Dong, Song ;

Xu, Chong-Rui ;

Chen, Hua-Jun ;

Wang, Zhen ;

Li, Pansong ;

Guan, Yanfang ;

Wang, Bin-Chao ;

Yang, Jin-Ji ;

Tu, Hai-Yan ;

Yang, Xue-Ning ;

Zhong, Wen-Zhao ;

Xia, Xuefeng ;

Yi, Xin ;

Zhou, Qing ;

Wu, Yi-Long .

CANCER CELL, 2023, 41 (10) :1763-+

[67] Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study [J].

Park, Ji Eun ;

Hong, Kyung Soo ;

Choi, Sun Ha ;

Lee, Shin Yup ;

Shin, Kyeong-Cheol ;

Jang, Jong Geol ;

Kwon, Yong Shik ;

Park, Sun Hyo ;

Choi, Keum-Ju ;

Jung, Chi Young ;

Eom, Jung Seop ;

Kim, Saerom ;

Seol, Hee Yun ;

Kim, Jehun ;

Kim, Insu ;

Park, Jin Han ;

Kim, Tae Hoon ;

Ahn, June Hong .

CLINICAL LUNG CANCER, 2024, 25 (04) :354-364

[68]

Patel SR, 2001, AID-CNCR1440>3.0.CO

[69]

2-0 Cancer, V5<1213, DOI [10.1002/1097-0142, DOI 10.1002/1097-0142]

[70] Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial [J].

Paz-Ares, L. ;

Spira, A. ;

Raben, D. ;

Planchard, D. ;

Cho, B. C. ;

Ozguroglu, M. ;

Daniel, D. ;

Villegas, A. ;

Vicente, D. ;

Hui, R. ;

Murakami, S. ;

Spigel, D. ;

Senan, S. ;

Langer, C. J. ;

Perez, B. A. ;

Boothman, A-M ;

Broadhurst, H. ;

Wadsworth, C. ;

Dennis, P. A. ;

Antonia, S. J. ;

Faivre-Finn, C. .

ANNALS OF ONCOLOGY, 2020, 31 (06) :798-806

← 2 3 4 5 6 7 8 9 10 11 →